

WAVETM

LIFE SCIENCES

\$100 Million
Follow-On Offering

LEERINK 
PARTNERS

Joint Bookrunner
December 2023

Leerink Partners Serves as Joint Bookrunner for Wave Life Sciences' (Nasdaq: WVE) \$100 Million Follow-On Offering

Key Transaction Highlights

- Confidentially marketed deal that publicly launched on December 6th (post-close) and priced overnight
- Base deal consisted of 20,000,000 ordinary shares at a price of \$5.00 per share, representing a 9.3% file to offer discount.
- Wave Life Sciences intends to use the net proceeds from this offering to advance its RNA editing pipeline of programs, to advance and accelerate the development of its INHBE program into the clinic, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures and general and administrative expenses.
- This is Leerink Partners' 6th bookrun offering for Wave Life Sciences and 52nd equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

MIAMI
1395 Brickell Avenue
Suite 800
Miami, FL 33131

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111